Prevention of mother-to-child transmission of HIV-1 infection: Alternative strategies and their cost-effectiveness

AIDS

Volumn 12, Issue 11, 1998, Pages 1381-1388

  Ratcliffe, Julie ^a   Ades, A E ^b   Gibb, Diana ^b   Sculpher, Mark J ^a   Briggs, Andrew H ^c  

^a BRUNEL UNIVERSITY   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Cost effectiveness; Costs; HIV vertical transmission; Risk reduction

Indexed keywords

ZIDOVUDINE;

ADULT; ARTICLE; BOTTLE FEEDING; CESAREAN SECTION; COST EFFECTIVENESS ANALYSIS; FEMALE; HEALTH CARE COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ADMINISTRATION; NEWBORN; PRIORITY JOURNAL; PUBLIC HEALTH; RISK; UNITED KINGDOM; VERTICAL TRANSMISSION;

EID: 0032581592     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199811000-00021     Document Type: Article

References (27)

1. Peckham C, Gibb D: Mother-to-child transmission of the human immunodeficiency virus. N Engl J Med 1995, 333:298-302.
2. Dunn DT, Newell ML, Ades AE, Peckham CS: Risk of human immunodeficiency virus type 1 transmission through breastfeeding. Lancet 1992, 340:585-588.
3. Connor EM, Sperling RS, Gelber R, et al.: Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS clinical trials group protocol 076 study group. N Engl J Med 1994, 331:1173-1180.
4. European Collaborative Study: Vertical transmission of HIV-1: maternal immune status and obstetric factors. AIDS 1996, 10:1675-1681.
5. Landesman SH, Kalish LA, Burns DN, et al.: Obstetrical factors and the transmission of human immunodeficiency virus type 1 from mother to child. The women and infants transmission study. N Engl J Med 1996, 334:1617-1623.
6. Mayaux MJ, Teglas JP, Mandelbrot L, Berrebi A, Gallais H, Matherton S: Acceptability and impact of zidovudine prevention on mother-to-child HIV 1 transmission in France. J Paediatr 1997, 131:857-862.
7. Fiscus SA, Adimora AA, Schoenbach VJ, et al.: Perinatal HIV infection and the effect of zidovudine therapy on transmission in rural and urban counties. JAMA 1996, 275:1483-1488.
8. British Medical Association, Royal Pharmaceutical Society of Great Britain: British National Formulary. Number 31. London: BMA, March 1996.
9. Centers for Disease Control and Prevention: Recommendations of the U.S. Public Health Service Task Force on the use of zidovudine to reduce perinatal transmission of human immunodeficiency virus. MMWR 1994, 43:1-20.
10. Clark L, Mugford M, Paterson C: How does the mode of delivery affect the cost of maternity care? Br J Obstet Gynaecol 1991, 98:519-523.
11. Regional Reproductive Review Project: British Notification Details by Area of Residence 1992-1994. London: Department of Epidemiology and Medical Statistics, St Bartholomew's and the Royal London School of Medicine and Dentistry; 1996.
12. Anon: Health Services Price Index. London: Department of Health; 1996.
13. Gibb DM, MacDonagh SE, Tookey PA, et al.: Uptake of interventions to reduce mother-to-child transmission of HIV in the United Kingdom and Ireland. AIDS 1997, 11:F53-F58.
14. Macfarlane A, Chamberlain G: What is happening to Caesarean section rates? Lancet 1993, 342:1005-1006.
15. Karlsson G, Johannesson M: The decision rules of cost effectiveness analysis. PharmacoEconomics 1996, 9:113-120.
16. Mauskopf J, Paul JE, Wichman DS, et al.: Economic impact of treatment of HIV-positive pregnant women and their newborn with zidovudine: implications for HIV screening. JAMA 1996, 276:132-138.
17. Mandelbrot L, Mayaux MJ, Bongain A, et al.: Obstetric factors and mother-to-child transmission of human immunodeficiency virus type-1: The French perinatal cohorts. Am J Obstet Gynecol 1996, 175:661-667.
18. Dunn DT, Newell ML, Mayaux MJ, et al.: Mode of delivery and vertical transmission of HIV-1: a review of prospective studies. Perinatal AIDS collaborative transmission studies. J Acquir Immune Defic Syndr 1994, 7:1064-1066.
19. Bazin B, Mandelbrot L, Parazzini F: A randomised trial to evaluate effectiveness of caesarean section in the prevention of HIV vertical transmission. XI International Conference on AIDS. Vancouver, July 1996 [abstract TuB2277].
20. Havens PL, Cuene BE, Holtgrave DR: Lifetime cost of care for children with HIV infection. Pediatr Infect Dis J 1997, 16:607-610.
21. Mandalia S, Beck EJ, Griffith R, et al.: The use, cost and outcome of hospital service provision for HIV infected children St. Mary's Hospital London 1986-94. XI International Conference on AIDS. Vancouver, July 1996. [abstract TuB2157].
22. Biggar RJ, Miotti PC, Taha TE et al.: Perinatal intervention trial in Africa: effect of a birth canal cleansing intervention to prevent HIV transmission. Lancet 1996, 347:1647-1650.
23. Kuhn L, Abrams EJ, Matheson PB, et al.: Timing of maternal-infant HIV transmission: associations between intrapartum factors and early polymerase chain reaction results. AIDS 1997, 11:429-435.
24. European Collaborative Study: Caesarean section and risk of vertical transmission of HIV-1 infection. The European Collaborative Study. Lancet 1994, 343:1464-1467.
25. Kind CF, for the Swiss HIV Study Group: Effects of zidovudine prophylaxis and elective caesarian section on vertical HIV transmission. XI International Conference on AIDS Vancouver. July 1996 [abstract TuC442].
26. Dunn DT, Brandt CD, Krivine A, et al.: The sensitivity of HIV-1 DNA polymerase chain reaction in the neonatal period and the relative contributions of intra-uterine and intra-partum transmission. AIDS 1995, 9:F7-F11.
27. Kalish LA, Pitt J, Lew J, Landesman S, Diaz C: Defining the time of fetal or perinatal acquisition of HIV-1 infection based on first positive culture. J Infect Dis 1997, 175:712-715.